Bruce Klein, MD, was recently awarded a 1-year, $38,500 grant from Vaxine, an Australian biotechnology company focusing on development of innovative vaccine technologies. This objective of this grant, for the project titled, “Developing Advax adjuvanted vaccine formulation against systemic fungi,” will be to formulate Advax (provided by Vaxine) with protective fungal antigens (provided by the Klein lab) to vaccinate against fungal infections and ultimately to translate the formulation to a human vaccine.